Nivagen v. Sun Pharma: SEZABY Phenobarbital Patent Case Transferred to New Jersey
Nivagen, Inc. brought an infringement action against Sun Pharmaceutical Industries and three related entities over two patents covering SEZABY (phenobarbital sodium) 100 mg/vial. After 589 days in the Eastern District of Texas, the case was transferred to the District of New Jersey, where it continues as case 2:25-cv-15210.
Pharmaceutical patent venue transfer: Nivagen vs. Sun Pharma’s SEZABY challenge
On January 23, 2024, Nivagen, Inc. filed Case No. 2:24-cv-00036 in the Eastern District of Texas alleging infringement of US11878076B2 and US11406598B2 — two patents covering SEZABY (phenobarbital sodium) 100 mg/vial, a formulation used in the treatment of neonatal seizures. The defendants named were Sun Pharmaceutical Industries, Inc. (U.S.), Sun Pharmaceutical Medicare, Ltd., Sun Pharma Advanced Research Company, Ltd., and Sun Pharmaceutical Industries, Ltd. — a coordinated set of entities spanning Sun’s U.S. and Indian operations.
The case did not reach a merits verdict in Texas. On September 3, 2025 — 589 days after filing — the Eastern District of Texas transferred the matter to the District of New Jersey, where it was opened as case 2:25-cv-15210 and remains active. A transfer under these circumstances typically signals that the transferee court was found to be a clearly more convenient forum, often due to witness location, corporate presence, or the locus of the accused activity.
The 589-day tenure in E.D. Texas before transfer is notable: it suggests the parties engaged in substantive pre-transfer litigation, including potential venue discovery and briefing, before the court ordered the shift. The public record does not disclose whether a consent agreement or contested motion drove the transfer, nor what claim construction or scheduling orders, if any, carry forward into the New Jersey proceeding. IP practitioners should monitor the New Jersey docket for updated scheduling orders and any carry-over rulings.
Filing to Case Transferred in 589 days
589 days in E.D. Texas before venue transfer — cases transferred out of this docket typically resolve faster in receiving courts
Venue transferred to D. New Jersey: what the shift means for both parties
What a venue transfer means in patent litigation
A transfer under 28 U.S.C. § 1404(a) moves the case to a more convenient or proper forum — it is not a dismissal and does not adjudicate the merits. All claims and defenses survive intact. The transferee court (D. New Jersey) inherits the docket but is not bound by the transferor court’s unreduced rulings. Practitioners should expect a new scheduling order and potentially different claim construction procedures in New Jersey.
No merits ruling — litigation continuesNivagen’s infringement claims move to a new venue
For Nivagen, the transfer is a procedural setback insofar as E.D. Texas had been a preferred plaintiff venue. However, the District of New Jersey is one of the most active and experienced pharmaceutical patent courts in the U.S., handling significant Hatch-Waxman and specialty pharma disputes. Nivagen’s infringement claims against both the U.S. and Indian Sun entities remain live. The strength of those claims will now be tested before a New Jersey judge.
Claims survive — new forum, same stakesSun Pharma secures a more favorable forum
The transfer to New Jersey is broadly consistent with a successful venue challenge by Sun Pharmaceutical, whose U.S. operations and relevant commercial activities are more naturally associated with New Jersey’s pharma corridor. The transfer does not resolve liability but places the case in a jurisdiction where defendants with strong local ties may find a more balanced procedural environment. Sun’s invalidity and non-infringement defenses remain fully available in the new forum.
Venue challenge likely succeededSEZABY market exclusivity timeline extended by litigation uncertainty
With the case now reopened in New Jersey as 2:25-cv-15210, the dispute over phenobarbital sodium formulation patents continues to cloud the competitive landscape for SEZABY. For generic entrants and specialty pharma companies monitoring this space, the transfer resets the litigation clock. Any potential 30-month stay implications under Hatch-Waxman, if applicable, and the ultimate validity of the two asserted patents will only be resolved after full New Jersey proceedings.
Market entry uncertainty continuesFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Nivagen, Inc. | Company | Pharmaceutical company — holder of US11878076B2 and US11406598B2 covering SEZABY phenobarbital sodiumSearch in Eureka ↗ |
| Defendant | Sun Pharmaceutical Industries, Inc. | Company | Sun Pharmaceutical Industries and three affiliates — global generic and specialty pharma groupSearch in Eureka ↗ |
| Co-Defendant | Sun Pharmaceutical Medicare, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Sun Pharma Advanced Research Company, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Sun Pharmaceutical Industries, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Andrew Thompson (Tom) Gorham | Attorney | Counsel for Nivagen, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Brent A. Batzer | Attorney | Counsel for Nivagen, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christopher Michael Bruno | Attorney | Counsel for Nivagen, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Melissa Richards Smith | Attorney | Counsel for Nivagen, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Shashank Upadhye | Attorney | Counsel for Nivagen, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Ty William Wilson | Attorney | Counsel for Nivagen, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William E. Davis , III | Attorney | Counsel for Nivagen, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Yixin H. Tang | Attorney | Counsel for Nivagen, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Davis Firm PC | Law Firm | Representing Nivagen, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gilliam & Smith LLP | Law Firm | Representing Nivagen, Inc.Search in Eureka ↗ |
| Plaintiff law firm | The Davis Firm PC (Longview) | Law Firm | Representing Nivagen, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Upadhye Tang, LLP | Law Firm | Representing Nivagen, Inc.Search in Eureka ↗ |
| Defendant counsel | Alexandra Olson | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Eric Hugh Findlay | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | J. Derek Vandenburgh | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Justin Oakland | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Peter M Kohlhepp | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Samuel T. Lockner | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Seung Sub Kim | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant law firm | Carlson Caspers Vandenburgh & Lindquist PA | Law Firm | Representing Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant law firm | Carlson, Caspers, Vandenburgh, Lindquist & Schuman PA | Law Firm | Representing Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant law firm | Findlay Craft PC | Law Firm | Representing Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Texas Eastern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The transfer entry does not constitute a merits ruling — no finding of infringement, validity, or invalidity has been made. The docket notation confirms the case was administratively closed in E.D. Texas and reopened in the District of New Jersey as 2:25-cv-15210. This procedural disposition preserves all claims and defenses. The phrasing ‘Case transferred… has been opened… [LIVE]’ confirms the litigation is ongoing, and any prior E.D. Texas scheduling or discovery orders may require confirmation or replacement by the receiving court.
US11878076B2 & US11406598B2 — Phenobarbital Sodium Formulation Patents
US11878076B2 (application no. US18/100804) and US11406598B2 (application no. US17/025881) both relate to SEZABY — phenobarbital sodium 100 mg/vial — a product used in the treatment of neonatal seizures. Phenobarbital is a long-established anticonvulsant, but patent protection in this context likely attaches to specific formulation innovations, dosing regimens, or delivery characteristics that differentiate the SEZABY product from prior-art phenobarbital preparations. The two patents suggest a layered protection strategy covering both the core formulation and subsequent improvements or method claims.
For a specialty pharmaceutical product targeting neonatal seizure management, formulation patents can serve as durable market exclusivity tools even for molecules with long generic histories. The assertion of two patents against Sun Pharma — a major global generics manufacturer with a dedicated advanced research division — suggests Nivagen views these patents as substantively defensible against an ANDA or 505(b)(2) challenge. Competitors developing or commercialising phenobarbital sodium injectable products should treat both patents as active blocking IP until the New Jersey court rules on validity and infringement.
Should you run an FTO against US11878076B2 and US11406598B2?
Any company developing, manufacturing, or planning to commercialise a phenobarbital sodium injectable product — particularly a 100 mg/vial presentation targeting neonatal populations — should conduct a freedom-to-operate analysis against both asserted patents before advancing to clinical or regulatory stages. With active litigation now in the District of New Jersey, the risk profile is live and the claim scope under judicial scrutiny. Generic applicants, contract manufacturers, and hospital formulary partners are all potentially exposed.
PatSnap Eureka’s FTO Search Agent can map the independent and dependent claim scope of US11878076B2 and US11406598B2 against your product specifications in minutes, flagging overlapping claim elements and identifying prior art that may support design-around or invalidity arguments. Eureka’s litigation monitoring layer also alerts you to new filings in the 2:25-cv-15210 New Jersey docket, so your IP team stays ahead of any claim construction orders that could narrow or expand the patents’ reach.
Run a freedom-to-operate analysis on US11878076B2 to assess your product’s exposure
Run FTO in Eureka →Similar phenobarbital sodium and neonatal formulation patent cases
Explore comparable pharmaceutical formulation infringement actions in the Eastern District of Texas and District of New Jersey involving injectable neonatal drug patents.
What this case signals for the pharmaceutical patent IP landscape
This transfer highlights the strategic importance of venue selection and early forum challenges in specialty pharma patent disputes.
E.D. Texas is no longer a guaranteed plaintiff-friendly venue for pharma IP
Sun Pharma’s apparent successful venue transfer after 589 days reflects a broader tightening of E.D. Texas jurisdiction over pharmaceutical patent cases following TC Heartland and subsequent precedent. Plaintiffs filing in Texas should expect robust early venue challenges, particularly where defendants have strong New Jersey or Delaware ties.
D. New Jersey is emerging as the de facto home for specialty pharma patent battles
With large pharma operations clustered in New Jersey’s corridor, the transferee court has deep Hatch-Waxman and formulation patent expertise. IP teams tracking SEZABY or phenobarbital sodium competitors should monitor the New Jersey docket at 2:25-cv-15210 for claim construction rulings that could set sector-wide precedent.
Nivagen v Sun — key questions answered
Nivagen asserted two patents: US11878076B2 (application US18/100804) and US11406598B2 (application US17/025881), both covering SEZABY phenobarbital sodium 100 mg/vial, a product used in the treatment of neonatal seizures.
The case was transferred on September 3, 2025, after 589 days in E.D. Texas. The public record indicates a ‘Case Transferred’ basis of termination. This is consistent with a successful venue challenge, typically under 28 U.S.C. § 1404(a), where the transferee court is found to be a clearly more convenient forum. The New Jersey case is live as 2:25-cv-15210.
Four Sun Pharma entities are named: Sun Pharmaceutical Industries, Inc. (U.S.), Sun Pharmaceutical Medicare, Ltd., Sun Pharma Advanced Research Company, Ltd., and Sun Pharmaceutical Industries, Ltd. This structure targets both the U.S. commercial arm and the Indian manufacturing and R&D entities.
No. The Eastern District of Texas closed the case via transfer without issuing any ruling on infringement, validity, or invalidity. All claims and defenses remain open in the District of New Jersey proceeding (2:25-cv-15210), where the litigation is ongoing as of the transfer date.
SEZABY is a phenobarbital sodium injectable product presented as 100 mg/vial, indicated for the treatment of neonatal seizures. Although phenobarbital is a long-established compound, Nivagen’s patents appear to cover specific formulation or method innovations that may differentiate SEZABY from prior phenobarbital preparations, making them potentially enforceable against generic or competing injectable products.
PatSnap Eureka searches patents and litigation data to answer instantly.